The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Roflumilast: a review of its use in the treatment of COPD
Open accessAbstract
COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation. COPD is associated with worsening airflow limitation over time and increased frequency of COPD exacerbations, leading to increased mortality and morbidity. The effects of COPD extend beyond the lungs, as multiple comorbidities may occur with COPD, including cardiovascular disease, diabetes mellitus, osteoporosis, depression, and pneumonia. COPD exacerbations are associated with a rapid worsening of baseline symptoms that requires prompt management and may necessitate hospitalization in the case of a severe episode. Patients with COPD exacerbations require urgent management of symptoms to prevent further worsening, and preventative steps may be taken to help reduce the number and frequency of future exacerbations. Roflumilast is a potent and selective inhibitor of the enzyme phosphodiesterase-4 that targets the systemic inflammation associated with COPD. Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface markers and inhibition of apoptosis. Several clinical trials evaluating roflumilast in the treatment of COPD have demonstrated significant improvements from baseline versus placebo in lung function, including increases in mean pre- and postbronchodilator forced expiratory volume in 1 second and forced vital capacity. Data suggest that roflumilast reduces moderate to severe exacerbations with the benefit most well established in patients with severe disease. Given this evidence, roflumilast, as part of a combination regimen with long-acting bronchodilators, appears to be a reasonable treatment option for patients with severe to very severe COPD associated with chronic bronchitis and a history of exacerbations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Self-citation
Cited by
COVID‐19 diagnosis and management: a comprehensive review
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., & Agrò, F. E. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13091 · Cited by 1,369
COPD Guidelines: A Review of the 2018 GOLD Report
Mirza, S., Clay, R. D., Koslow, M. A., & Scanlon, P. D. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.05.026 · Cited by 444
Barreiro, E., Puig-Vilanova, E., Salazar-Degracia, A., Pascual-Guardia, S., Casadevall, C., & Gea, J. (2018) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00798.2017 · Cited by 30
Roflumilast: A potential drug for the treatment of cognitive impairment?
Sugin, L. J. S., Murugesan, A., Bindu, M., & Sunil, K. N. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135281 · Cited by 24
Metadata
- Authors
- Wedzicha, J., Calverley, P., & Rabe, K.
- Venue
- International Journal of Chronic Obstructive Pulmonary Disease
- Publisher
- Informa UK Limited
- Published
- 2016-01
- Volume
- 11
- Pages
- 81
- ISSN
- 1176-9106 (ISSN-L)
- 1178-2005
- OpenAlex
- W2230518119
- Cited by
- 168
- References
- 1
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Roflumilast: a review of its use in the treatment of COPD. https://app.cochat.ai/papers/10.2147/copd.s89849
- The paper
- Wedzicha, J., Calverley, P., & Rabe, K. (2016). Roflumilast: a review of its use in the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s89849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.